J. Scarisbrick, C. Querfeld, O. Akilov, M. Bagot, R. Córdoba, R. Cowan, A.M. García -Sancho, L.J. Geskin, A.O. Huen, J. Jadwani, Y. Liu, H. Zhao, S. Morris, P.L. Ortiz-Romero, A. Patel, L.C. Pinter-Brown, R.M. Pujol, P. Quaglino, N.S. Saba, R. Vuppugalla, Y.H. Kim
{"title":"A-195 正在进行的一项2期、开放标签、多中心、单臂研究的初步结果,该研究评估了皮肤T细胞淋巴瘤患者每4周服用一次莫加单抗的剂量表","authors":"J. Scarisbrick, C. Querfeld, O. Akilov, M. Bagot, R. Córdoba, R. Cowan, A.M. García -Sancho, L.J. Geskin, A.O. Huen, J. Jadwani, Y. Liu, H. Zhao, S. Morris, P.L. Ortiz-Romero, A. Patel, L.C. Pinter-Brown, R.M. Pujol, P. Quaglino, N.S. Saba, R. Vuppugalla, Y.H. Kim","doi":"10.1016/j.ejca.2024.114402","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"211 ","pages":"Article 114402"},"PeriodicalIF":7.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A-195 Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma\",\"authors\":\"J. Scarisbrick, C. Querfeld, O. Akilov, M. Bagot, R. Córdoba, R. Cowan, A.M. García -Sancho, L.J. Geskin, A.O. Huen, J. Jadwani, Y. Liu, H. Zhao, S. Morris, P.L. Ortiz-Romero, A. Patel, L.C. Pinter-Brown, R.M. Pujol, P. Quaglino, N.S. Saba, R. Vuppugalla, Y.H. Kim\",\"doi\":\"10.1016/j.ejca.2024.114402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11980,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"211 \",\"pages\":\"Article 114402\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0959804924010980\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804924010980","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
A-195 Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma
期刊介绍:
The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.